

In the Claims:

Amend claims 16, 26 and 28 as follows:

Sub  
B2  
16. (Amended) A transdermal therapeutic system with a content of a first active ingredient; said first active ingredient comprising at least one of candesartan and one of its pharmaceutically suitable esters or salts.

Sub  
B2  
B3  
26. (Amended) The transdermal therapeutic system of claim 23 wherein the system is a matrix system comprising:  
  
an impermeable covering layer;  
  
at least one active ingredient-containing contact adhesive matrix layer or at least one ingredient-containing matrix layer coated with a contact adhesive;  
  
a detachable protective layer; and  
  
an active ingredient comprising at least one of candesartan and one of its pharmaceutically acceptable esters or salts.

Sub  
B3  
B4  
28. (Amended) The transdermal therapeutic system of claim 23 wherein the membrane system comprises:  
  
an impermeable covering layer;  
  
an active ingredient-containing reservoir or an active ingredient-containing reservoir layer;  
  
a microporous or semipermeable membrane;  
  
an optional contact adhesive layer; and  
  
an active ingredient comprising at least one of candesartan and one of its pharmaceutically acceptable esters or salts.

**BEST AVAILABLE COPY**